Drug intelligence / Profile preview

VLA2001

Development stage: Discontinued
Lead developer: Valneva
Modality: Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

VLA2001 is an inactivated, adjuvanted whole-virus SARS-CoV-2 vaccine developed for the prevention of COVID-19. It consists of highly purified, chemically inactivated whole virus particles with high spike protein density and is formulated with two adjuvants: alum and CpG 1018. The CpG 1018 adjuvant is designed to enhance immunogenicity by shifting the immune response toward a Th1 profile and increasing antibody levels compared to alum-only formulations. The vaccine induces both humoral (neutralizing antibodies) and cellular (T-cell) responses against multiple viral proteins including spike (S), nucleocapsid (N), and membrane (M). Developed using a vero cell-based platform, it leverages manufacturing technology from Valneva’s licensed Japanese encephalitis vaccine IXIARO. VLA2001 was the first inactivated whole-virus COVID‑19 vaccine to receive standard marketing authorization in Europe but has since had its authorization withdrawn[2][3][4][5][6].

Brand names: COVID-19 Vaccine (inactivated, adjuvanted) ValnevaValneva COVID-19 vaccine
Other names: Valneva COVID-19 vaccine

Beyond the preview

Go deeper on VLA2001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VLA2001.

Explore the full profile